安进 2026年季度报告

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM10-Q (Mark One)QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 orTRANSITION REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc.(Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ofincorporation or organization) (805) 447-1000(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Trading Symbol(s) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and(2)has been subject to such filing requirements for the past 90 days.Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Non-accelerated filer☐ Large accelerated filer☑Accelerated filer☐Smallerreportingcompany☐Emerginggrowthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☑ As of July30, 2026, the registrant had 540,632,005 shares of common stock, $0.0001 par value, outstanding. AMGEN INC. INDEX DEFINED TERMS AND PRODUCTSPART I—FINANCIAL INFORMATIONItem1.FINANCIAL STATEMENTSCONDENSED CONSOLIDATED STATEMENTS OF INCOMECONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMECONDENSED CONSOLIDATED BALANCE SHEETSCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITYCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSItem2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONSItem3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKItem4.CONTROLS AND PROCEDURESPART II—OTHER INFORMATIONItem1.LEGAL PROCEEDINGSItem1A.RISK FACTORSItem2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSItem 5.OTHER INFORMATIONItem6.EXHIBITSINDEX TO EXHIBITSSIGNATURES Defined Terms and Products Defined terms We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related, as wellas names of other companies, which are provided below. Products The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names areprovided below. AMGEN INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(In millions)(Unaudited) AMGEN INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In millions, except per-share data) AMGEN INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In millions)(Unaudited) AMGEN INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSJune 30, 2026(Unaudited) 1. Summary of significant accounting policies Business Amgen Inc. (including its consolidated subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a globalbiotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.We operate our business in oneoperating segment: human therapeutics. See Note 2, Segment and other information. Basis of presentation The interim unaudited financial information for the three and six months ended June 30, 2026 and 2025, has been prepared inaccordance with GAAP and includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated) thatAmgen considers necessary for a fair presentation, in all material respects, of its condensed consolidated results of operations for thoseperiods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and thenotes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2025, and with the condensed consolidatedfinancial statements and the notes thereto contained in our Quarterly Report on Form 10-Q f